Observational studyBMC infectious diseases2025
Effects of inactivated COVID-19 vaccination on HIV viremia and reservoir size: a longitudinal cohort study.
Observational study in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Dynamics of HIV reservoirs following repeated anti-SARS-CoV-2 vaccination.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundVaccination is regarded as the most effective and cost-efficient mean of managing COVID-19. Whether receiving inactivated vaccine leads to plasma viral load (pVL) rebound and affects HIV reservoirs size has been a major concern for people living with HIV (PLWH). In this study we performed a longitudinal observational study to explore the dynamic changes of pVL and HIV-1 total DNA with PLWH after vaccination with inactivated COVID-19 vaccine.
methodsInformation and venous blood samples from PLWH were collected prevaccination (BC1), three weeks after the first vaccination (BC2), four weeks after the second dose (BC3), six months after the second dose (BC4), and two weeks after the third dose (BC5) to test RBD-specific IgG antibody, plasma viral load (pVL), HIV-1 total DNA and CD4+ T cell count.
resultsA total of 25 PLWH participated in this study, with a median age of 34 (IQR 28.5 - 40.0) years. No significant difference in proportion of undetectable pVL group, pVL ≥ 20 cp/ml group and pVL < 20 cp/ml group was observed among five time points (p = 0.506). Significant difference was observed in total HIV-1 DNA copies among different time points in both group of CD4+ T cells ≤ 300 and > 300. In the group of nadir CD4+ T cells > 300, pairwise comparison of five sets of data showed that total HIV-1 DNA copies at BC5 was significantly lower than BC1 (P = 0.043) and BC3 (P = 0.008). And duration of HIV infection was positively correlated with HIV-1 DNA copies at BC4 (R = 0.729, p = 0.007) and BC5 (R = 0.690, p = 0.013), S/CO value of RBD-specific-IgG at BC3 were negatively correlated with HIV-1 total DNA copies at time points of BC2 (R=-0.713, p = 0.009) and BC3 (R=-0.587, p = 0.045).
conclusionsReceiving inactivated COVID-19 vaccine didn't significantly affect pVL. HIV-1 total DNA copies had a downward trend after vaccination. Duration of infection and IgG titer might be correlated with HIV-1 total DNA copies after vaccination.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.